Bayer sweetens Monsanto deal
Print Edition
GERMAN pharmaceutical and crop chemicals manufacturer Bayer AG says talks with Monsanto Co have advanced and it is now willing to offer more than US$65 billion, a 2 percent increase on its previous offer for the world’s largest seeds company.
“Both sides are gradually nearing consensus,” one person familiar with the matter said.
Monsanto has also agreed to open its books for Bayer to conduct due diligence checks on the company’s business, two sources close to the matter said.
Bayer’s previous offer was already the largest all-cash takeover attempt on record with an agreement with Monsanto aimed at giving the German company a shot at grabbing the top spot in the fast-consolidating farm supplies industry, combining its crop science business with Monsanto’s strength in seeds.
Bayer now says it is prepared to offer US$127.50 per share in a negotiated deal, up from its previous offer of US$125 per share.
But German daily newspaper Rheinische Post also reported late on Monday that an offer of US$130 per share may be necessary to get a deal with Monsanto “in a swift and friendly way.”
Bayer was still considering all options regarding Monsanto, including striking a friendly deal, making a hostile bid or pulling its offer, a person familiar with the matter told Reuters.
Analysts at brokerage Equinet said they “infer from Bayer’s statement that failure to agree a deal at US$127.50/share could imply a risk to Monsanto shareholders of either a hostile bid at a lesser consideration, or no deal at all.”
Analysts from Baader Helvea disagreed. “We still expect a bid per share in the US$130-135 range before Monsanto comes to the table. As such, we continue see the Bayer shares remaining under pressure as the negotiations continue,” they said in a note.
In a brief statement, Monsanto said on Monday it had been engaged in “constructive” negotiations with Bayer, during which it received the updated non-binding proposal of US$127.50 per share in cash.
The Saint Louis-based company added that it was continuing these conversations as it evaluated Bayer’s offer, as well as proposals from other parties it did not name. It cautioned that there was no certainty that any deal would occur.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
